Opto Circuits Q2FY10 consolidated net sales up 18% at Rs 256 cr

Image
Announcement Corporate
Last Updated : Jan 20 2013 | 12:15 AM IST

Opto Circuits (India) Ltd. (OCI), one of the leading Indian companies that develop, manufacture and market medical devices for global markets, today announced its financial results for the second quarter ended September 30th, 2009.

Consolidated net sales grew by 18 % to Rs 255.73 crore, as compared to Rs 217.02 crore in the corresponding period of last year. Consolidated net profit grew by 18% to Rs 66.93 crore, as compared to Rs 56.73 crore in the corresponding period of last year.

On a standalone basis, the company’s net sales grew by 16 % to Rs 120.87 crore, as compared to Rs 104.36 crore in the corresponding period of last year. Net profit stood at Rs 38.9 crore, as compared to Rs 38.58 crore in the corresponding period of last year.

Half Year Performance:

Consolidated net sales for the half year ended September 30, 2009, grew by 23% to Rs. 486.09 crore, as compared to Rs. 394.38 crore in H1FY09. Net profit for half year ended September 30, 2009 was at Rs. 126.13 crore, as compared to Rs. 101.72 crore in H1FY09, registering a growth of 24%.

Earnings per Share for H1FY10 stood at Rs. 6.90 (Basic) and Rs. 6.88 (Diluted).

Management Comments:

Vinod Ramnani, Chairman and Managing Director, OCI, commented, “The strategic and long term agreements signed through our wholly-owned US subsidiary, Criticare Systems Inc., have helped us diversify our product portfolio and expand our presence in many key markets in Europe, United States and Latin America.”

Quarter Highlights:

During the quarter, the company has successfully raised Rs. 400 crore through the QIP route. OCI has allotted 2,14,30,484 equity shares to institutional investors at Rs. 186.65 (Rs. 10/- face value and Rs. 176.65 Premium).

The quarter saw OCI’s wholly-owned US-based subsidiary, Criticare Systems Inc. (CSI), sign a long-term agreement with a European manufacturer and distributor of medical equipment. The agreement involves the supply of private label patient monitoring systems by CSI to the partner as well as cooperation in sales and distribution of anaesthetic gas delivery products in several key markets, both in the United States and Europe.

CSI also signed a strategic multi-year OEM contract with another US company to private label its anaesthesia monitor for the signed partner. The agreement leverages CSI’s unique anesthesia gas monitoring technology in applications that involve the calibration and maintenance of anesthesia equipment in some of the leading hospitals in the United States.

OCI developed a new pocket sized finger pulse Oximeter (SPO2 monitor), M50 NanoSAT™. M50 NanoSAT™ is one of the smallest and lightest of such monitors and has received CE Approval for marketing and distribution in key markets like Europe, Asia and Latin America.

OCI signed long-term development agreement with a leading OEM customer. The agreement provides for a joint development program focused on a new modular and MRI-compatible patient monitoring system. The system will be based on Criticare’s new eVision™ platform.

About Opto Circuits (India) Ltd.
Opto Circuits (India) Ltd. (OCI) (BSE Code: 532391; NSE Symbol: OPTOCIRCUI) is a 100 percent EOU and a leading manufacturer of healthcare equipment in India. The product profile includes digital thermometers, sensors, pulse oximeters, patient monitoring systems, stents, catheters and other innovative products. In 2001, OCI acquired 60 per cent stake in Advanced Micronic Devices (AMDL) to market and distribute its products in India. Mediaid came into existence with the acquisition of the patient monitoring division of Palco Labs, US, in end-2003 and it now directly markets OCI’s products in the US. OCI acquired EuroCor GmbH in 2006. EuroCor manufactures Cardiac Stents of various types, including Drug Eluting Coronary stents. In April 2007, OCI ventured into new product segments - Urology, Gastroenterology, Gynaecology and Orthopaedics after acquiring Devon Innovations Private Limited (Bangalore) and Ormed Medical Technology Limited (Chennai). OCI completed the acquisition of US based Criticare Systems, Inc. in April 2008. Criticare designs, manufactures, and markets leading edge patient monitoring systems, vital signs monitors and gas benches for a wide range of hospitals and alternate health care environments throughout the world.
Visit us at www.optoindia.com

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 30 2009 | 6:45 PM IST

Next Story